Thank you, Elliott, and good morning. Today, Dana and I are looking forward to giving you some insight into the second quarter numbers that we released last night and discussing the drivers we're seeing in the medical professional liability and workers' compensation markets I'll provide some commentary regarding the market conditions we're seeing, and then Dana will provide the consolidated results and key drivers of our investment returns and book value. The results we released last night represent a solid quarter and highlight both the challenges and opportunities in the markets in which we operate. At a high level, there's been relative stability in the current accident year loss ratio albeit at higher level than in 2022, and a decline in favorable prior accident year reserve development. Underwriting expenses are stable for the quarter relative to the prior year and investment results have improved significantly. The competitive market and challenging claims environment that are impacting our current and prior accident year loss ratios have been persistent within our industry for some time now, and we expect these to continue, providing us some indication of what we can expect in coming quarters. With that background, I'll walk you through the results reported in our key segments. The lower underwriting result in our Specialty P&C segment was driven primarily by a reduction in favorable prior accident year reserve adjustments. We have historically experienced considerable favorable development in this segment, though the amount of development in recent years has been lower than the average for the past decade, while we still booked favorable development in the quarter Our assessment of the claims environment has made us cautious about reducing the level of outstanding reserves. We continue to monitor increased severity trends in a handful of our legacy jurisdictions. We also have responded to the difficult environment by setting higher initial case reserves on reported claims. We booked a current accident year loss ratio of 84.7%, up slightly from last year. We recognized net favorable prior accident year reserve development of $7 million in the quarter, primarily in our Medical Technology Liability business. The claims environment that I described in detail on last quarter's call remains with us for the foreseeable future and we continue working diligently to manage losses and mitigate the impact of social inflation. Given the current environment, the impact of any change may not be obvious in a single quarter, instead, we expect the results from our efforts to be evident over time. Our gross written premium increased by 1% from a year ago with new business from our specialty line exceeding expectations and contributing to the top-line growth. Our strategy in the E&S and specialty market is to retain the business we like, reduce limits where we can, and walk away when we cannot achieve our targeted price and to be opportunistic on new accounts. Consistent with that strategy, we were at $12 million of new business in the quarter, up from $8 million last year. The Medical Technology Liability new business production increase year-over-year despite a very competitive environment. Premium retention for the segment overall was 83%, a point below last year's, as we continue to focus on price over volume. Price competition is the largest driver of business not renewing with us. We also continue to see healthcare consolidation and practice changes affecting retention levels and leading to the loss of some policyholder accounts in both the standard and specialty books. Overall, pricing in the Specialty P&C segment increased by 6% in the quarter, continuing to compound upon last year's 6% increase. Underwriting expenses were down slightly from last year as we continue to focus on efficiencies and process improvements, systems integration, and statutory consolidation. An increase in ceding commission, which reduces underwriting expenses contributed to the decline in expenses in this quarter. Compensation and related costs have increased in the quarter compared to the prior year, there's a number of open positions have been filled. The expense ratio of 26.5% was slightly higher as a result of lower earned premium this quarter compared to 2022. Turning to the Workers' Compensation Insurance segment, gross written premium decreased by $1 million in the quarter with a challenging and competitive market impacting both retention and renewal pricing. In our traditional business, renewal pricing was down 7% and retention was 80% for the quarter. We saw an increase in audit premium for the quarter and increased our estimate of carried EBUB premium, both of which helped to offset the decrease in retention and pricing. We also saw growth in new business in our traditional book adding nearly $6 million of new accounts in the quarter. The current accident year loss ratio of 72.6% remained consistent with our Q1 loss ratio. It was approximately a point higher than the second quarter of 2022. A portion of this increase was due to higher headcount in our claims department and the associated compensation costs which flow into our loss ratio through unallocated loss adjustment expense. We also saw an increase in estimated losses recognized under our reinsurance contracts annual aggregate deductible, which contributed to the increase in loss ratio. We booked no change in the prior accident year reserves compared to favorable development of $2 million last year. This led to an increase in the calendar year loss ratio. Expenses increased compared to last year with compensation costs, travel expenses, and IT costs driving the increase. The increase in compensation costs primarily reflected the higher headcount in this segment as we filled open positions. The segment expense ratio was 35% for the quarter. I'll finish with the Segregated Portfolio Cell Reinsurance segment, which posted a profit of just under $1 million for the quarter and the Lloyds Syndicates segment, which generated a small profit. Now I'd like to turn the call over to Dana to share our consolidated results and some highlights from the balance sheet and investment returns. Dana?